Literature DB >> 33841681

CircRNAs as promising biomarkers of inflammatory bowel disease and its associated-colorectal cancer.

Yuting Xu1, Xinwei Xu1, Dickson Kofi Wiredu Ocansey1,2, Hua Cao3, Wei Qiu3, Qiang Tu3, Fei Mao1.   

Abstract

In recent years, research on the pathogenesis of inflammatory bowel disease (IBD) and its associated-colorectal cancer has been well documented to involve environmental, genetic, immune, and intestinal microbiota factors. Evidence indicates that, regardless of the current high global incidence of IBD with over 3.5 million cases in Europe and North America only, it continues to emerge in newly industrialized countries across Asia, Middle East, and South America. Individuals with IBD have significant increased risk of gastrointestinal and extra-intestinal malignancies, particularly, colorectal cancer (CRC) and lymphomas. Among the significant areas of exploration in IBD and its associated-CRC is the search for effective and reliable diagnostic and prognostic markers, and treatment targets. To this effect, the role of non-coding RNAs in IBD and its associated-CRC has attracted research attention, among which microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) get more detailed exploration while little is known about circular RNAs (circRNAs). This review focuses on the emerging role of circRNAs in the diagnosis, prognosis, and treatment of IBD and its associated-CRC. It introduces the biogenesis of circRNAs and brings an up-to-date report on those found within IBD and CRC environment, as well as their participation toward the promotion or suppression of the conditions, and their diagnostic potentials. AJTR
Copyright © 2021.

Entities:  

Keywords:  Circular RNA; biomarker; colorectal cancer; diagnosis; inflammatory bowel disease; prognosis

Year:  2021        PMID: 33841681      PMCID: PMC8014397     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  94 in total

1.  MicroRNA 301A Promotes Intestinal Inflammation and Colitis-Associated Cancer Development by Inhibiting BTG1.

Authors:  Chong He; Tianming Yu; Yan Shi; Caiyun Ma; Wenjing Yang; Leilei Fang; Mingming Sun; Wei Wu; Fei Xiao; Feifan Guo; Minhu Chen; Hong Yang; Jiaming Qian; Yingzi Cong; Zhanju Liu
Journal:  Gastroenterology       Date:  2017-02-11       Impact factor: 22.682

2.  Identification of differentially expressed circular RNAs in human colorectal cancer.

Authors:  Peili Zhang; Zhigui Zuo; Wenjing Shang; Aihua Wu; Ruichun Bi; Jianbo Wu; Shaotang Li; Xuecheng Sun; Lei Jiang
Journal:  Tumour Biol       Date:  2017-03

3.  Induction of the transcription factor IRF-1 and interferon-beta mRNAs by cytokines and activators of second-messenger pathways.

Authors:  T Fujita; L F Reis; N Watanabe; Y Kimura; T Taniguchi; J Vilcek
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

4.  Integrative regulatory mapping indicates that the RNA-binding protein HuR couples pre-mRNA processing and mRNA stability.

Authors:  Neelanjan Mukherjee; David L Corcoran; Jeffrey D Nusbaum; David W Reid; Stoyan Georgiev; Markus Hafner; Manuel Ascano; Thomas Tuschl; Uwe Ohler; Jack D Keene
Journal:  Mol Cell       Date:  2011-06-30       Impact factor: 17.970

5.  Metagenomic analysis of microbiome in colon tissue from subjects with inflammatory bowel diseases reveals interplay of viruses and bacteria.

Authors:  Weiwei Wang; Juan Jovel; Brendan Halloran; Eytan Wine; Jordan Patterson; Glenn Ford; Sandra OʼKeefe; Bo Meng; Deyong Song; Yong Zhang; Zhijian Tian; Shawn T Wasilenko; Mandana Rahbari; Salman Reza; Troy Mitchell; Tracy Jordan; Eric Carpenter; Karen Madsen; Richard Fedorak; Levinus A Dielemann; Gane Ka-Shu Wong; Andrew L Mason
Journal:  Inflamm Bowel Dis       Date:  2015-06       Impact factor: 5.325

6.  Circular RNA circCCDC9 acts as a miR-6792-3p sponge to suppress the progression of gastric cancer through regulating CAV1 expression.

Authors:  Zai Luo; Zeyin Rong; Jianming Zhang; Zhonglin Zhu; Zhilong Yu; Tengfei Li; Zhongmao Fu; Zhengjun Qiu; Chen Huang
Journal:  Mol Cancer       Date:  2020-05-09       Impact factor: 27.401

7.  Different motif requirements for the localization zipcode element of β-actin mRNA binding by HuD and ZBP1.

Authors:  Hak Hee Kim; Seung Joon Lee; Amy S Gardiner; Nora I Perrone-Bizzozero; Soonmoon Yoo
Journal:  Nucleic Acids Res       Date:  2015-07-07       Impact factor: 16.971

Review 8.  Identifying and Characterizing circRNA-Protein Interaction.

Authors:  William W Du; Chao Zhang; Weining Yang; Tianqiao Yong; Faryal Mehwish Awan; Burton B Yang
Journal:  Theranostics       Date:  2017-09-26       Impact factor: 11.556

9.  CircHIPK3 promotes colorectal cancer growth and metastasis by sponging miR-7.

Authors:  Kaixuan Zeng; Xiaoxiang Chen; Mu Xu; Xiangxiang Liu; Xiuxiu Hu; Tao Xu; Huiling Sun; Yuqin Pan; Bangshun He; Shukui Wang
Journal:  Cell Death Dis       Date:  2018-04-01       Impact factor: 8.469

10.  Association of lncRNA-p53 regulatory network (lincRNA-p21, lincRNA-ROR and MALAT1) and p53 with the clinicopathological features of colorectal primary lesions and tumors.

Authors:  Vahid Chaleshi; Shiva Irani; Masoud Alebouyeh; Reza Mirfakhraie; Hamid Asadzadeh Aghdaei
Journal:  Oncol Lett       Date:  2020-04-07       Impact factor: 2.967

View more
  4 in total

1.  Identification of Three Potential circRNA Biomarkers of Polycystic Ovary Syndrome by Bioinformatics Analysis and Validation.

Authors:  Pengyu Huang; Shengrong Du; Yunhong Lin; Zhiqing Huang; Haiyan Li; Gangxin Chen; Suzhu Chen; Qingfen Chen; Lincui Da; Hang Shi; Wei Wei; Lei Yang; Yan Sun; Beihong Zheng
Journal:  Int J Gen Med       Date:  2021-09-22

2.  Exosomal circSHKBP1 participates in non-small cell lung cancer progression through PKM2-mediated glycolysis.

Authors:  Wenbiao Chen; Donge Tang; Junqi Lin; Xiaoming Huang; Shaoming Lin; Guanle Shen; Yong Dai
Journal:  Mol Ther Oncolytics       Date:  2022-02-02       Impact factor: 7.200

3.  circ‑LRP6 contributes to osteosarcoma progression by regulating the miR‑141‑3p/HDAC4/HMGB1 axis.

Authors:  Yali Yu; Guixiang Dong; Zijun Li; Yan Zheng; Zhisong Shi; Guanghui Wang
Journal:  Int J Oncol       Date:  2022-02-25       Impact factor: 5.650

Review 4.  Engineering autonomous closed-loop designer cells for disease therapy.

Authors:  Mohamed Mahameed; Martin Fussenegger
Journal:  iScience       Date:  2022-01-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.